At #ASTRO2026, a collection of new research will explore how genomic information can help clarify pivotal treatment decisions for patients with cancer. As a key example, join us for an oral presentation from Angela Jia, M.D., Ph.D., that aims to answer a key question: Which individuals with intermediate-risk prostate cancer are most likely to benefit from short-term androgen-deprivation therapy when receiving dose-escalated radiotherapy? In an ancillary analysis of the landmark Phase III NRG/RTOG 0815 clinical trial, Dr. Jia will present findings on whether the Decipher® Prostate Genomic Classifier test can help predict which patients are most likely to benefit from adding short-term androgen deprivation to dose-escalated radiotherapy. | Featured Presentation Information | 📄 Abstract: #312 📅 Date/Time: Tuesday, September 29, 3:55–4:05 p.m. ET 📍 Location: Room 210 We’re also looking forward to additional ASTRO 2026 presentations examining treatment intensification and the role of transcriptomic biomarkers in prostate cancer radiation therapy treatment decisions. | Additional Key Oral Presentations | 🔹 Evaluation of PAM50 Molecular Subtypes in Post-Prostatectomy Salvage Radiotherapy: An NRG Oncology-RTOG 0534 Analysis 🎤 Presenter: Shuang Zhao, MD, MSE, University of Texas MD Anderson Cancer Center 📄 Abstract: 6 Date/Time: Sunday, September 27, 1:30–1:40 p.m. ET 📍 Location: Grand Ballroom 🔹The Role of Docetaxel In Addition to Salvage Radiation and Androgen Deprivation In Men with High Risk Prostate Cancer Post-Prostatectomy: Results of NRG GU002 🎤 Presenter: Mark Hurwitz, M.D., FASTRO, New York Medical College/Westchester Medical Center Health 📄 Abstract: 250 Date/Time: Tuesday, September 29, 12:40–12:50 p.m. ET 📍 Location: Room 210 🔹 Multi-institutional Transcriptomic Characterization of Radiorecurrent Prostate Cancer and Prognostic Biomarkers After Salvage Re-irradiation in the F-SHARP Clinical Trial 🎤 Presenter: Abhishek Solanki, M.D., M.S., Loyola University Medical Center 📄 Abstract: 314 📅 Date/Time: Tuesday, September 29, 4:15–4:25 p.m. ET 📍 Location: Room 210 🔹 Long-Term Transcriptomic Analysis of NRG/RTOG 9601: A Phase 3 Study of Salvage Radiotherapy for Prostate Cancer with or without Anti-Androgen Therapy 🎤 Presenter: Krishnan Patel, M.D., University of Texas MD Anderson Cancer Center 📄 Abstract: 315 📅 Date/Time: Tuesday, September 29, 5:35–5:40 p.m. ET 📍 Location: Room 205 | Resources | 🔗 For additional presentations and info on Veracyte’s activities at ASTRO 2026: veracyte.com/company/event/a… #RadOnc #PrecisionOncology #ClinicalTrials #RealWorldData #DecipherProstate #TeamVeracyte Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit - veracyte.com/legal/cautionar…

Eight studies, including analyses from multiple clinical trials, leveraging our Decipher® Prostate Genomic Classifier test and whole-transcriptome data will be presented at the 2026 American Society for Radiation Oncology Annual Meeting (#ASTRO26), taking place from September 26 through September 30 in Boston. | Key Highlights | The presentations include analyses from: 🔹 Phase II and III clinical trials 🔹 Decipher Genomic Research for Intelligent Discovery (#DecipherGRID) research 🔹 National real-world studies Collectively, these presentations will further explore the potential clinical value of understanding tumor biology at the molecular level and how genomic testing can help personalize treatment decisions for #ProstateCancer patients across different stages of disease. Of note, clinical trial analyses will specifically examine Decipher’s prognostic value in assessing disease risk and predictive value in identifying which patients may benefit from treatment intensification, including adding androgen-deprivation therapy (ADT) to radiation. | Resources | 🔗 Read the full press release - investor.veracyte.com/news-r… 🔗 Event information - veracyte.com/company/event/a… 📄 Decipher Prostate test - veracyte.com/tests/decipher-… 📄 Decipher GRID data resource - veracyte.com/innovation/deci… #RadOnc #PrecisionOncology #ClinicalTrials #RealWorldData #TeamVeracyte Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit - veracyte.com/legal/cautionar…

During Thyroid Cancer Awareness Month, Veracyte recognizes that an indeterminate thyroid nodule result often leads to critical questions about malignancy risk, the potential for unnecessary surgery, and the most appropriate next step. For these patients, every management decision begins with diagnostic clarity. Afirma® Genomic Sequencing Classifier (GSC) delivers a clinically actionable benign or suspicious result, helping clinicians conclusively rule out surgery for many patients while providing additional variant and fusion information to help guide treatment for suspicious nodules. More than 400,000 patients have benefited from insights provided by Afirma GSC. As the most utilized molecular test for thyroid nodules in the Medicare population based on Medicare claims data*, Afirma is trusted by healthcare providers to support informed management decisions and to provide greater confidence in patient care. 🔗 Learn how Afirma GSC can support your thyroid nodule management - veracyte.com/tests/afirma-th… *Based on claims for CPT codes 81546, 0026U, 0245U as of 8/11/2026 – found at data.cms.gov/ Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit - veracyte.com/legal/cautionar… #ThyroidCancerAwarenessMonth #ThyroidCancer #ThyroidNodules #MolecularTesting #PrecisionMedicine #AfirmaThyroid

Prostate Cancer Awareness Month (PCAM) is a time to focus on the people behind every diagnosis – and the questions, decisions, and care teams that shape each patient’s path forward. Behind every study, every test result, and every treatment decision is a person looking for answers. With that in mind, PCAM also serves as an opportunity to reflect on how ongoing research into tools such as genomic testing are helping inform more personalized conversations about prostate cancer care. Veracyte is incredibly proud that the Decipher® Prostate Genomic Classifier continues to help providers and patients get answers. Over the years, a wide-ranging collection of publications supports the use of the Decipher Prostate test in prostate cancer care decision-making, helping clinicians and their patients navigate treatment choices with clarity through genomic insights. Veracyte continues to build on that foundation. This work takes time, investment, and follow-through, and reflects Veracyte’s broader commitment to helping advance prostate cancer care. As we honor Prostate Cancer Awareness Month, our team wrote a piece to discuss the latest clinical research featuring the Decipher Prostate test and how it helps patients. | Key Topics Covered | 🔹 How the #DecipherProstate test works 🔹 Results from the ENZAMET Trial 🔹 The latest research on predicting cancer progression 🔹 A preview of new studies being presented at ASTRO 2026 🔗 For more, read the full piece here -  veracyte.com/company/blog/fr… #ProstateCancer #ProstateCancerAwareness #PrecisionMedicine Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit - veracyte.com/legal/cautionar…

Today, we announced the acquisition of Convergent Genomics, adding Convergent Genomics’ UroAmp platform, including its proprietary urinary tumor DNA (utDNA) technology, to our product portfolio. UroAmp has been clinically validated in non-muscle invasive bladder cancer (NMIBC), including therapy-response monitoring and post-treatment surveillance, and is supported by a robust and growing body of evidence. | Why This Matters | 🔹 Expanded capabilities: This acquisition strengthens our ability to deliver powerful complementary genomic insights from urine, tissue, and blood, helping guide bladder cancer care across the patient journey. 🔹 First Product: Our initial test will be intended to help determine whether patients who have had Bacillus Calmette-Guerin (BCG) induction therapy are likely to benefit from maintenance treatment. We expect to commercialize this test in late 2028, subject to reimbursement timelines. 🔹 Forward direction: We plan to expand our use of the UroAmp platform to additional indications, including intravesical maintenance therapy monitoring and surveillance following treatment with curative intent. | Resources | 📄 Read the full press release - investor.veracyte.com/news-r… 🔗 Learn more about Veracyte - veracyte.com Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit: veracyte.com/legal/cautionar… #Veracyte $VCYT #CancerDiagnostics #PrecisionMedicine #Acquisition #InvestorRelations

Over the last three decades, advances in prostate cancer screening and molecular testing have led to significant improvements in early detection and patient outcomes. However, a prostate cancer diagnosis is often only the beginning of a long, personal journey. On that path, patients face difficult questions, like: 🔹 What does my diagnosis mean? 🔹 How aggressive is my cancer? 🔹 What are my treatment options? 🔹 What are the risks and benefits? 🔹 Is more treatment likely to help me? 🔹 Could some treatment be avoided? In honor of Prostate Cancer Awareness Month, we wrote an article that takes a closer look at what comes after diagnosis, addressing the patient experience and some important clinical considerations along the way. As a central part of that discussion, we address how advancements in genomic testing are helping to inform more personalized conversations about care. 🔗 Read our thoughts here - veracyte.com/company/blog/fr… At Veracyte, we believe patients deserve answers that reflect the biology of their disease. Through the Decipher® Prostate Genomic Classifier, we are working to help clinicians and patients navigate complex prostate cancer treatment choices with genomic insights supported by a growing body of research. #ProstateCancerAwareness #ProstateHealth #CancerResearch #DecipherProstate Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit - veracyte.com/legal/cautionar…

A new publication shares results from primary and biomarker analyses of the phase 2 SURE-01 trial. The trial evaluated sacituzumab govitecan prior to radical cystectomy in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based neoadjuvant chemotherapy. Molecular profiling using the Decipher® Bladder Genomic Subtyping Classifier indentified higher pathologic complete response rates to treatment with sacituzumab govitecan in patients with non-luminal tumors (46%) than among those with luminal tumors (14%). This finding highlights the potential value of molecular subtyping for indentifying differences in treatment responses and advancing a more personalized approach to bladder cancer management. ➡️ Read the complete findings here: ascopubs.org/doi/10.1200/JCO… | Resources | 🔗 Learn more about Decipher Bladder: veracyte.com/tests/decipher-… 📄 Explore all Decipher Bladder Scientific Publications: veracyte.com/resources/scien… #MIBC #MolecularSubtyping #ClinicalResearch #DecipherUrologicCancers Note: This post contains forward-looking statements, which involve risks and uncertainties. For more information visit - veracyte.com/cautionary-note…

A newly published study demonstrates the potential of our TrueMRD™ platform in one of the most challenging settings to predict recurrence: Stage IA lung adenocarcinoma. Unlike approaches that focus on a limited set of mutations, this study used TrueMRD, which takes a whole-genome approach from landmark test through monitoring. Using the TrueMRD proprietary algorithm in this study, they were able to analyze thousands of coding and non-coding variants unique to each patient's tumor. 📖 Read the publication - jmdjournal.org/article/S1525… | Highlights from the study | 🔬 Focused on the earliest-stage disease. Researchers followed a cohort of Stage IA lung adenocarcinoma patients for up to 10 years after surgery to understand which patients ultimately experienced recurrence. 🧬 Whole-genome insights matter. By analyzing thousands of patient-specific genomic variants—not just selected hotspots—the platform detected molecular residual disease at extremely low levels, including signals from across the non-coding genome that targeted approaches may not include. ⏱️ Earlier insight into recurrence. In patients who ultimately recurred and had positive MRD results, the assay detected recurrence a median of 16.7 months before clinical or imaging confirmation, demonstrating the potential value of whole-genome monitoring for long-term surveillance. As evidence continues to grow, studies like this can illustrate how the TrueMRD platform, which uses comprehensive whole-genome analysis may help clinicians better monitor and understand residual disease and personalize follow-up care for patients with early-stage cancer. As a reminder, TrueMRD is commercially available for muscle-invasive bladder cancer today, but multiple studies have already been completed, and there are more than 20 studies in the pipeline across several indications. 📖 Read the publication: jmdjournal.org/article/S1525… #LungCancer #MRD #PrecisionOncology #TrueMRD Note: This post contains forward-looking statements, which involve risks and uncertainties. For more information visit - veracyte.com/cautionary-note…

🚨 Don’t miss the recent episode of the patient-focused Save Your Thyroid podcast on surgical decision-making with indeterminate #ThyroidNodules, featuring Dr. Joshua Klopper, the Medical Director for #Endocrinology at Veracyte and one of the investigators on the original clinical utility study of the first-generation Afirma® test. In the interview, Dr. Klopper explains the essentials of molecular testing for #ThyroidPatients in a clear and approachable way. In the process, he describes why as many as 70-80% of thyroid surgeries for indeterminate nodules are unnecessary and how #MolecularDiagnostics, like  the Afirma Genomic Sequencing Classifier (GSC) test, can help clarify #ThyroidCancer risk. | Key Topics | 🔹 The Bethesda classification system 🔹 The profound impact of unnecessary thyroid surgeries on patients 🔹 How the #AfirmaGSC test works and how specific mutations can affect risk 🔹 What the future of molecular testing technology in #ThyroidCare may hold Thank you, Jennifer Holkem, for hosting a fantastic discussion! 🔗 Watch the full episode here: piped.video/watch?v=cP29-7nQ… | About the #AfirmaGSC | 🔗 The Afirma Genomic Sequencing Classifier helps clinicians conclusively rule out surgery and confidently guide treatment for thyroid nodules. Explore clinical evidence and how the Afirma GSC test works: veracyte.com/tests/afirma-th… #AfirmaThyroid #ThyroidHealth #TeamVeracyte Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit - veracyte.com/legal/cautionar…

The “High-Risk Breast Cancer Management with Test-Directed Chemotherapy” virtual session is now available on-demand on GenomeWeb! Prof. Rob Stein, Chief Investigator of the OPTIMA trial, walks through the study’s first  results originally presented at ASCO 2026. The #OPTIMA trial demonstrated that more than two-thirds of node-positive patients with early-stage, ER-positive and HER2-negative #BreastCancer who previously might have received chemotherapy can now safely avoid it based on the Prosigna® Breast Risk of Recurrence (ROR) test results. Veracyte Medical Director for Breast Cancer, Dr. Kelly Marcom, joins Prof. Stein and discusses how these findings and the recent U.S. launch of the #Prosigna Breast ROR test may impact treatment decisions for patients with clinically high-risk ER+ breast cancer. | What to Expect | From the trial data to its clinical implications, you’ll get to: 🔹 Review the OPTIMA trial and its initial results 🔹 Connect the findings to their potential impact on treatment decisions for pre- and post-menopausal patients with up to 9 positive nodes 🔹 Hear Prof. Rob Stein and Veracyte's Dr. Kelly Marcom answer audience questions that dig deeper on clinically-relevant topics surrounding the use of the Prosigna ➡️ Click here to instantly watch the recording - event.on24.com/wcc/r/5348737… | Prosigna Resources | Explore Clinical Resources - veracyte.com/tests/prosigna-… View Sample Reports - veracyte.com/tests/prosigna-… #CancerPrognosis #CancerDiagnostics #OncologyResearch #CancerResearch Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit - veracyte.com/legal/cautionar…

Today, we announced strong second-quarter 2026 financial results, reflecting continued momentum across our #CancerDiagnostics portfolio: 🔹 $150.3 million in total revenue, up 15% year over year 🔹 $145.7 million in testing revenue, up 19% year over year 🔹 $44.0 million in adjusted EBITDA, representing 29.2% of revenue Q2 was also a milestone quarter, marked by the U.S. launches of the Prosigna® Breast Risk of Recurrence Test and the TrueMRD™ Monitoring Test for patients with muscle-invasive bladder cancer. Together, these offerings expand our ability to serve more patients across the cancer care continuum. | Resources | 🔹 View #Q2Earnings Presentation - investor.veracyte.com/static… 🔹 Explore our technology and pipeline - veracyte.com/innovation/tech… 🔹 Learn about some of our active clinical studies - veracyte.com/innovation/clin… #Veracyte #InvestorRelations #PrecisionMedicine $VCYT Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit - veracyte.com/cautionary-note…

We will report financial results for the second quarter of 2026 on July 30, 2026 at 4:30 PM EDT. Join our conference call and webcast to learn more about the financial results and receive a general business update. Access the live audio webcast here - investor.veracyte.com/events… #Q2Earnings #FinancialResults #InvestorRelations #Biotech #Diagnostics $VCYT #CancerDiagnostics #PrecisionMedicine #DecipherUrologicCancers #ProsignaBreastRORTest #AfirmaGSC #TrueMRDforMIBC Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit - veracyte.com/cautionary-note…

More personalized cancer care starts with clearer answers. In this Investor’s Business Daily feature by @IBD_AGatlin, our CEO @MarcStapley highlights how Veracyte’s genomic tests, such as the Prosigna® Breast and Decipher® Prostate tests, are helping guide treatment decisions to support a new era of #PrecisionOncology. Read the full story: investors.com/news/technolog… | Clinical Resources | #ProsignaBreastRORTest - veracyte.com/tests/prosigna-… #DecipherProstate - veracyte.com/tests/decipher-… #CancerDiagnostics  #BreastCancer #ProstateCancer #TeamVeracyte Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit - veracyte.com/legal/cautionar…

The Veracyte team is Boston-bound this week for the #AHNS2026 Annual Conference, joining leaders in #HeadandNeckOncology from July 18th through the 22nd to support innovation in #HeadandNeckCancer care. Visit Booth #301 to talk with our team and learn how the Afirma® Genomic Sequencing Classifier (GSC) uses transcriptome-wide analysis of over 21,000 genes from patient fine-needle aspiration (FNA) samples to help conclusively rule out surgery and confidently guide treatment for #ThyroidNodules. You can also ask our team about the latest updates to Afirma® GRID (Genomic Resource for Intelligent Discovery), a proprietary research-use-only* data resource, designed to help advance the understanding of #ThyroidNodules and #ThyroidCancer at the molecular level. Plus, you’ll have a chance to hear from physicians at the University of Vermont about how they are using transcriptome-wide thyroid nodule analysis with #Afirma to evaluate #ThyroidCancer. We look forward to seeing you there! *Afirma GRID data is for research use only and is not intended to guide patient management. | Podium Presentation Details | Presentation: Evaluating Molecular Profiling to Predict Malignancy in Thyroid Nodules and High-risk Thyroid Cancer Session: Proffered Papers 30 - Cancer Technologies and Diagnostics 📅 Date / Time: Monday, July 20, 2026 at 4:00 PM - 5:30 PM | Resources | 🔗 Explore Afirma GSC - veracyte.com/tests/afirma-th… 📄 Download the Afirma 2025 Research Collection - veracyte.com/afirma-2025-res… #AfirmaThyroid #ThyroidHealth #ClinicalOncology #ThyroidCare #TeamVeracyte Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information, veracyte.com/legal/cautionar…

In case you missed the news at #ASCO2026, a recent analysis of #ProstateCancer patient samples from the ENZAMET trial demonstrated that the Decipher® Prostate test could identify which men with metastatic prostate cancer may benefit from adding the chemotherapy docetaxel to standard hormonal therapy (also known as triplet therapy), and who may safely avoid it. #ENZAMET Trial is an international, randomized Phase III study conducted by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) led by Christopher Sweeney, MBBS, and Ian D. Davis, MBBS, PhD, FRACP, FAChPM. The pre-specified biomarker analysis using the Decipher Prostate test was performed in 634 patients with a median follow-up of 5.6 years. | Key Study Outcomes | 🔹Patients with higher Decipher scores (>0.85) who received triplet therapy had significantly improved five-year overall survival compared to those on standard hormone therapy alone. 🔹Patients with lower Decipher scores (≤0.85) showed no evidence of benefit from adding chemotherapy, suggesting it may be safely avoided. | A Growing Body of Evidence | The ENZAMET results provide the first Level 1B evidence for genomic-guided decisions on triplet therapy in metastatic prostate cancer. The ENZAMET study expands the Decipher evidence base for metastatic prostate cancer into triplet therapy, with findings consistent with STAMPEDE and CHAARTED trials showing that patients with higher Decipher scores receive greater benefit from treatment intensification. The cumulative #ClinicalResearch validates the Decipher Prostate test across the full disease continuum, from active surveillance to metastatic disease, including triplet therapy | Resources | 🧬 For more on the Decipher Prostate test - veracyte.com/tests/decipher-… 📄 Explore Decipher Prostate scientific publications - veracyte.com/resources/scien… #DecipherUrologicCancers #PrecisionMedicine #CancerPrognosis #CancerDiagnostics #CancerResearch Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit - veracyte.com/legal/cautionar…

New @CBSLosAngeles coverage of the landmark #OPTIMA trial shows how the Prosigna® Breast Risk of Recurrence (ROR) test can help clinicians and patients understand whether chemotherapy may be beneficial or safely avoided. 🎬 Watch the segment: cbsnews.com/losangeles/video… | About the #ProsignaTest | 🔗 Clinical resources - veracyte.com/tests/prosigna-… 🔗 How to order - veracyte.com/tests/prosigna-… #ProsignaBreastRORTest #BreastCancer #PrecisionMedicine #CancerDiagnostics #TeamVeracyte Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit: veracyte.com/legal/cautionar…

New opportunity to hear the presentation of the #OPTIMA trial’s first results that were presented at #ASCO2026. Please join Chief Investigator Prof. Rob Stein for a virtual presentation of these findings in the upcoming webinar, “High-Risk Breast Cancer Management with Test-Directed Chemotherapy” hosted by Precision Medicine Online. The #OPTIMA trial demonstrated that more than two-thirds of node-positive patients with early-stage, ER-positive and HER2-negative #BreastCancer who previously might have received chemotherapy can now safely avoid it based on the Prosigna® Breast Risk of Recurrence (ROR) test results. Prof. Stein will be joined by Veracyte's Medical Director for Breast Cancer, Dr. Kelly Marcom, to discuss the potential impact of these findings and discuss the recent U.S. launch of the #Prosigna Breast ROR test may have on treatment decisions for patients with clinically high-risk ER+ breast cancer. | What to Expect | From the trial data to its clinical implications, you’ll get to: 🔹 Review the OPTIMA trial’s complete set of first results shared at ASCO 🔹 Explore how these findings may impact treatment decisions for pre- and post-menopausal patients with up to 9 positive nodes 🔹 Join the discussion with Prof. Rob Stein and Veracyte's Dr. Kelly Marcom ➡️ Reserve your spot here to learn more about this practice-changing evidence -event.on24.com/wcc/r/5348737… #CancerDiagnostics #OncologyResearch #CancerResearch @ucl Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit - veracyte.com/legal/cautionar…

Come meet us at #ENDO2026! Stop by Booth #4407 to connect with our team and learn how the Afirma® GRID (Genomic Resource for Intelligent Discovery), a proprietary research-use-only* database, is designed to help advance the understanding of #ThyroidNodules and #ThyroidCancer at the molecular level. What Can You Do with Afirma GRID Data? We share the Afirma GRID data resource with the research community to help accelerate scientific discoveries. The Afirma GRID data resource enables researchers and clinicians to uncover new insights into thyroid nodule and thyroid cancer biology by providing access to: 🧬 >300K whole-transcriptome profiles 🔒 Up to 46 locked gene expression signatures *Afirma GRID data is for research use only and is not intended to guide patient management. | The Afirma GRID Resources | Learn more about Afirma GRID - afirma.com/afirma-grid/ Download the Afirma 2025 Research Collection - veracyte.com/afirma-2025-res… | Additional ENDO Information | Event information - veracyte.com/company/event/e… Join Us at Exhibit Hall Theater #1: "Afirma Molecular Testing: Unique Situations and New Prognostic Development" 📅 Sunday, June 14  | 2:30–3:30 PM CT #AfirmaThyroid #ThyroidResearch #Endocrinology #GenomicResearch #TeamVeracyte Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit: veracyte.com/legal/cautionar…

We're excited to be back in Chicago this week for the #ENDO2026 Annual Meeting! Just weeks after being here for ASCO, our focus now shifts to learning with and from the #endocrinology community. Be sure to visit Booth #4407 to meet our team and learn how Veracyte utilizes transcriptome-wide analysis on every fine-needle aspiration (FNA) sample to generate an Afirma® Genomic Sequencing Classifier report that provides comprehensive molecular insights to support informed clinical decision-making. Attend our product theater on Sunday, June 14, featuring physicians from Brigham and Women’s Hospital discussing their experience with #AfirmaGSC and how it supports confident thyroid nodule management. | Product Theater Details | Presentation: Afirma Molecular Testing: Unique Situations and New Prognostic Development Presenters: Drs. Athanasios Bikas and Theodora Pappa (Brigham and Women’s Hospital) join Dr. Josh Klopper (Veracyte) 📅 Date / Time: Sunday, June 14 at 2:30 PM – 3:30 PM 📍 Location: Exhibit Hall Theater #1 We look forward to seeing you there! | Resources | 🔗 Event information: veracyte.com/company/event/e… 📄 Download the Afirma 2025 Research Collection: veracyte.com/afirma-2025-res… #Endocrinology #ThyroidNodules #ThyroidHealth #ClinicalEndocrinology Note: veracyte.com/legal/cautionar…

Congratulations to @UCL and the #OPTIMA investigator team on this incredible research featured on BBC Breakfast. 👏 Stories like Aileen Pritchard’s highlight the power of #PrecisionOncology in helping identify patients who can safely avoid unnecessary chemotherapy while still receiving the care that’s right for them. We’re proud that Veracyte was part of this important work. The Prosigna® Breast Risk of Recurrence (ROR) Test is now also available for ordering in the U.S., helping support more personalized treatment decisions for patients with early-stage #BreastCancer. | About Prosigna Test | #ProsignaRORTest Clinical Resources - veracyte.com/tests/prosigna-… How to order the #ProsignaBreastTest - veracyte.com/tests/prosigna-… #Oncology #Prosigna #BreastCancerResearch Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit: veracyte.com/legal/cautionar…